Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Klomp

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
The Journal of Clinical Investigation|December 2, 2025
Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancerZheng Zhong, Xinang Cao, Pei-Ju Liao, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stressJay R Anand, Gaith N Droby, Sayali Joseph, et al.
NAR Cancer|March 21, 2025
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stressJay R Anand, Gaith N Droby, Sayali Joseph, et al.
Cancer Research|November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C InhibitorsA Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor ResistanceKristina Drizyte-Miller, Seamus E Degan, Ryan D Mouery, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Science Translational Medicine|October 23, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapyXiuting Liu, John M Baer, Meredith L Stone, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Investigation|December 2, 2025
Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancerZheng Zhong, Xinang Cao, Pei-Ju Liao, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stressJay R Anand, Gaith N Droby, Sayali Joseph, et al.
NAR Cancer|March 21, 2025
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stressJay R Anand, Gaith N Droby, Sayali Joseph, et al.
Cancer Research|November 7, 2023
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C InhibitorsA Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor ResistanceKristina Drizyte-Miller, Seamus E Degan, Ryan D Mouery, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Science Translational Medicine|October 23, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapyXiuting Liu, John M Baer, Meredith L Stone, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Science (New York, N.Y.)|June 6, 2024
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancerJennifer E Klomp, J Nathaniel Diehl, Jeffrey A Klomp, et al.
Science Signaling|September 30, 2025
Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancerPriya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, et al.
Pageof 2